Physician profile
Michael Don Kirkham
NPI 1861478638
$2,192.45
in general payments reported to CMS, 2019-2025
36 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $189 · 2021: $285 · 2022: $337 · 2023: $262 · 2024: $486 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.57 | 2021-2025 | |
| Lilly USA, LLC | $187.09 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $180.70 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.52 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $118.00 | 2020-2025 | Veozah |
| Novo Nordisk INC | $97.04 | 2019-2023 | Wegovy |
| Amarin Pharma, INC. | $93.12 | 2020-2021 | |
| Pfizer INC. | $90.56 | 2019-2024 | |
| Amgen INC. | $74.09 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.88 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $60.27 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $57.36 | 2020-2024 | Airsupra, Farxiga, Breztri |
| Dynavax Technologies Corporation | $41.57 | 2024-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $38.72 | 2019-2024 | |
| Dexcom, INC. | $37.82 | 2024-2025 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $32.84 | 2024-2025 | Flucelvax, Fluad |
| Axsome Therapeutics, INC. | $31.61 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $28.39 | 2023 | Qelbree |
| Cranial Technologies, INC | $25.28 | 2019-2021 | |
| Team 1, LLC | $24.48 | 2024 | |
| Merck Sharp & Dohme LLC | $23.08 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.46 | 2022 | |
| Edwards Lifesciences Corporation | $22.24 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceuticals, INC. | $18.29 | 2021 | |
| Shield Therapeutics INC | $16.34 | 2025 | |
| Qiagen, LLC | $15.44 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.28 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.34 | 2024 | Zoryve |
| Shire North American Group INC | $13.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.88 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $12.68 | 2019 | |
| Medtronic, INC. | $12.28 | 2022 | |
| Teleflex LLC | $12.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.94 | 2022 | |
| Organon LLC | $11.78 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kirkham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.